Onivyde Approval History
FDA Approved: Yes (First approved October 22, 2015)
Brand name: Onivyde
Generic name: irinotecan liposomal
Dosage form: Injection
Previous Name: MM-398
Company: Merrimack Pharmaceuticals, Inc.
Treatment for: Pancreatic Cancer
Onivyde (irinotecan liposome injection) is a liposomal formulation of the topoisomerase I inhibitor irinotecan indicated for the treatment of post-gemcitabine metastatic adenocarcinoma of the pancreas.
Development History and FDA Approval Process for Onivyde
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.